PetMedix partners with Zoetis on companion animal mAbs

Animal Health

PetMedix is partnering with Zoetis (the market leader in companion animal antibody therapeutics). Using transgenic technologies, they aim to develop species-specific companion animal monoclonal antibody therapies (mAbs). Zoetis already has experience in this field having already taken three successfully to market.

PetMedix’s part of the collaboration will involve research, looking into the main focus points for treatments. Meanwhile, Zoetis will be in charge of manufacturing and marketing these therapies.

“Using transgenic technologies, they aim to develop species-specific companion animal monoclonal antibody therapies“

Tom Weaver, the Chief Executive at PetMedix, expressed his excitement towards the collaboration: “Bringing together our unique pet antibody discovery engine with their proven ability to not just develop antibodies, but also make them a commercial success, is set to be a winning combination. PetMedix’s mission is to elevate expectations in pet care, and we feel that this collaboration is another step towards that.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.

See all the latest jobs in Animal Health
Return to news